Weekly thought on $AEMD, $DFFN, $IBIO, $LRAD, TRXC

Just when you thought the broad market is recovering, more heat is coming from the sellers. SP500 was down this week and after hour so far is also pointing down. However, if you look at the much bigger time-frame (monthly in this case), the recent downturn is just simple normal correction. You can see that the uptrend is still within the three parallels uptrend lines. We are still in the bull market!

I’m still very long on both $LRAD and $TRXC. I wrote another piece on $TRXC and you can read it by clicking -> here.

$LRAD is still working on building the handle in the potential multi-years Cup & Handle breakout.The handle is pretty much completed (blue rectangular box), and the only thing we are all waiting for is to see a breakout over the $2.63 when news of more sales of mass notification system are announced. I believe this little company won’t be so little anymore by the end of this year. Why? Because it’s superior technology in mass notification systems will be in demand sooner or later. Not to mention that they have another trump card in their sleeve- it’s their recent acquisition that has the technology to notify all mobile users by specific location. Together with their mass notification long-range omni-directional acoustic devices, it has the best mass notification package for cities, governments, military, public and private organization to reach the maximum public at the quickest time in the most efficient manner.

Something is definitely up with $IBIO. I don’t know what it is but there seemed to be a major accumulation going on with this stock.For the past 12 weeks, the stock has been trending up slowly and steadily.

I never get tired of repeating myself about why I don’t worry about this stock. It has the plant-based protein expression technology that our future society needed. Not to mention the coming filing of IND for their lead therapeutic candidate IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. This one take a bit longer incubation time. And when it’s ready, watch out!

$AEMD is all about its magical hemopurifier. Once we hear about the update from FDA regarding the direction in commercial pathway, this will rocket higher.Although a down week, the overall trend since mid-November of last year is still UP.

Somebody is really working very hard to shake the $DFFN tree. I’ll remain steadfast in this one because I want to see progress on their Phase 1/2 trial on the stroke treatment. This is going to be very interesting when UCLA starts testing their TSC drug on live stroke victims during ambulance runs. Any positive responses from the stroke victims who received the TSC drug is going to rocket this one in a majestic way.

Thanks to $TRXC and $IBIO, my port gained slightly despite corrections from the rest of the positions.